IPO 2.0 #futuregrowth #withoutCanopy, page-54

I have to say though, the article is objective.

Though we all know these are the main issues that AusCann are primarily addressing in order to gain maximum market share and consumer and prescriber trust.

A quality product (check) backed by quality evidence (pending several months when they announce initiation by 2019 ending).

When AusCann announces full details, this will make mainstream media.

They literally will take the nation by storm by doing really the first extensive clinical trial for the best and most sought after product.

Godspeed.